Author Archives: Forest Ray PhD

R-107 Stops PAH Progression, Reverses Hypertension in Rats

An investigational therapy called R-107 completely stopped the progression of pulmonary arterial hypertension (PAH) in a rat model and may become the first medicine to reverse the increasing blood pressure characteristic of the disease, a study suggested. Now, R-107’s developer, Claritas Pharmaceuticals, plans to begin clinical testing…

Tyvaso DPI Earns FDA Priority Review Status

The U.S. Food and Drug Administration (FDA) has granted priority review status to the application seeking approval of Tyvaso DPI — a dry powder inhaled formulation of treprostinil — for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Priority review shortens…

PHA Publishes Guide on Risk Factors, Treatments in Newborn PH

The Pulmonary Hypertension Association (PHA) has published a guide to educate healthcare providers and parents on persistent pulmonary hypertension of the newborn (PPHN). The goal, the PHA said, is to help identify the disease right away, so as to start early treatment to prevent complications for the baby.

Tenax Buys PH Precision Med, Plans Trial for Oral Imatinib

Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first…

Prolargin Shows Early Promise as PAH Biomarker

The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was…